Jump to Navigation
Home

Main menu

  • Home
  • News
  • Markets Map
  • Sentiments
  • Topics
  • Data
  • Comments
  • Images
  • Blog
  • About

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • Discussions
  • Jamie Dimon's Fate in Shareholder Hands: JPMorgan...
  • Fed officials dampen speculation of imminent bond tapering
  • Committee nears final vote on immigration bill
  • Fed officials dampen speculation of imminent bond tapering
  • Ask Matt: How do investment banks move markets?
  • Enron no lesson to traders as EU probes oil-price...
  • JPMorgan Shareholders Fond Of This Dimon Guy, Would Like...
  • DealBook: Court Hears Appeal of Ex-Director of Goldman
  • Jamie Dimon Keeps CEO, Chairman Titles, but at What Cost?
  • Bankers' bonuses: European watchdog says many more...

    Comparative Effectiveness Research

    Sat, 10/03/2009 - 10:44 EDT - Mathew Yglesias
    • Comments
    • health care
    • uncat

    cerbrief_onpage 1
    To perhaps make the point from yesterday’s Health Care in 1500 post a bit less obliquely, medicine is a complicated technical subject. And both historically and presently, just jiggering with different ways of paying for medicine hasn’t sufficed to wring ineffective or even counterproductive treatment methods out of the system. People who are ailing want to be cured, of course, but in a first-order sense they also just want treatment in a way that can surpass anyone’s knowledge of whether treatment would be useful. And doctors, too, are in the business of prescribing treatments and have been in that business since long before they had any effective treatments whatsoever to dispense.
    Thus insofar as we want to make the allocation of health care resources not just fairer, but actually better we need to do comparative effectiveness research and try to figure out what will actually help people:
    With the volume of new medical devices, drugs, and other treatments coming into the U.S. health care system, sorting through the details of each product can be a cumbersome task. Health care providers obviously want to choose the best remedy for their patients based on evidence, not anecdotes or (potentially worse) solely on information received from companies trying to promote their product. Thus, comparative effectiveness research will fill a massive information gap that has left health professionals and patients without the proper evidence to assess which treatments work best for a given condition. [...]
    What’s more, a better understanding of which medical treatments work and which don’t could save money. It’s estimated that one-third of procedures and treatments administered in the United States have no proven benefit and account for up to $700 billion annually in current spending. Moreover, some of these treatments can have harmful side effects, produce worse health outcomes, and then, as a result, add to the soaring costs of medical care.
    Now whether this will save money or not in a budgetary sense over the long run is a question for CBO analysts and such. I don’t think it really matters. The point is that spending $700 billion a year on ineffective and counterproductive treatments is a terrible idea and wringing that spending out of the system is a great idea. Whether that $700 billion ends up getting “saved” and recycled into something else (preschool, bigger televisions, whatever) or ends up being repurposed into $700 billion in additional useful health care spending, we win either way. The point is just that a really fair and efficient way of delivering witchcraft to people isn’t so wonderful and we need to also focus on figuring out how to help people and not just “treat” them.


    • Original article
    • Login or register to post comments
     

    Related

    • Sens. Kyl, McConnell, and Roberts Want to Preserve the Waste in Public Sector Health Care

      Conservatives continue to be right to point out that achieving the sort of health care cost savings progressives are talking about is easier said than done. That said, I continue to be baffled as to how it is that they keep thinking the main point here is to castigate the progressives trying to make things better rather than castigating the people who are actually making the cost savings difficult.

    • Delivery System Day: Chris Jennings

      Chris Jennings served as a senior health care adviser to the White House from 1993 to 2000. He wasn't quite a czar, but close. And so he is particularly sensitive to the political structuring of some of this stuff.

    • Health minister threatened with ejection from royal college

    • Incentives Don’t Work

      By James Kwak

    • Health Care Reform: Supply, Demand, Price Effects and Shortages

      Earlier I wrote about the effects of pre-existing condition reform on insurance companies and health care providers.  In this post I want to talk more broadly about demand for health care services, supply, the price of health care procedures, and shortages.

    • Will Delivery System Reform Be Health Care’s Waterloo?

    • A Problem Unique to Private Medicine?

      This New York Times' investigation of a rogue cancer unit within a Philadelphia Veteran's Administration hospital is disturbing stuff. In essence, it seems that Dr. Gary Kao has been performing bradychardias -- a treatment for prostate cancer -- with a terribly high error rate, and using a variety of clerical tricks to cover his mistakes. No one has died, but dozens have suffered.

    • The Not-So-Awful Truth About Canadian Health Outcomes

      Toronto General Hospital (Wikimedia)

    • Medical care and comparative effectiveness

      The idea is to have a commission examine which procedures should not receive full Medicare reimbursement.  I favor spending cuts for Medicare so for me it's a go.  Megan McArdle considers some basic issues.  I'll add or second a few points:

    • Genetically Tailored Medicine

      Two roads diverged in a wood, and I, I took the one less traveled by, And that has made all the difference.                                              —Robert Frost

    Latest

    CBS Is Investigating How A Reporter's Computer Was Compromised
    CBS Is Investigating How A Reporter's...
    INSTANT MBA: Don't Aspire For A Higher Title
    INSTANT MBA: Don't Aspire For A Higher Title

    User login

    • Create new account
    • Request new password
    • Click on the icon to sign in with your social network login or enter your Bullfax.com login

    Our Blog

    • Did Iceland make it through the crisis?
    • Marks & Spenser, Bank Loans in China, Vodafone and Asian Stocks in Our News for Today 05/21/2013
    • Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 1669.16 0.17% FTSE: 6803.87 0.71% Nikk.: 15381.02 0.13% DAX: 8472.20 0.19% HSI: 23366.369 -0.54% FX: EUR/GBP: 1.1741 USD/EUR: 1.2907 JPY/USD: 102.465 Commodities: Gold: 1374.95

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • Discussions